Gamida Cell: Omidubicel Follow Up Data Shows 63% Overall Survival At Three Years

Gamida Cell Ltd. (GMDA) reported long term follow-up data and health-related quality of life scores of patients treated with omidubicel in patients with blood cancers. The data showed an overall survival and disease-free survival of 63% and 56% at three years, respectively, as well as durable long-term hematopoiesis and immune competence.

Overall well-being health-related quality of life scores for patients treated with omidubicel showed clinical benefit compared to standard of care, the company said.

Ronit Simantov, Chief Medical Officer of Gamida Cell, said: "As we approach the PDUFA date of January 30, 2023, and upon potential FDA approval, we are prepared to execute our plan that ensures access to those patients who can benefit from omidubicel as quickly as possible."

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT